Alkem Laboratories Sustainability Profile
Alkem Laboratories Limited, a prominent player in the pharmaceutical industry, is headquartered in Mumbai, India. Founded in 1973, the company has established a strong presence in various operational regions, including North America, Europe, and Asia. Alkem is renowned for its extensive portfolio of generic and branded formulations, as well as active pharmaceutical ingredients (APIs), catering to diverse therapeutic areas such as anti-infectives, cardiology, and gastroenterology. With a commitment to quality and innovation, Alkem Laboratories has achieved significant milestones, including numerous approvals from regulatory authorities worldwide. The company is recognised for its robust research and development capabilities, which underpin its unique product offerings. Alkem's market position is further solidified by its consistent growth and notable achievements, making it a trusted name in the global healthcare landscape.
DitchCarbon Score
How does Alkem Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alkem Laboratories's score of 20 is lower than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alkem Laboratories's reported carbon emissions
In 2024, Alkem Laboratories reported total carbon emissions of approximately 101,568,000 kg CO2e, comprising 19,249,000 kg CO2e from Scope 1 and 82,319,000 kg CO2e from Scope 2 emissions. This data reflects a consistent reporting of emissions over the past few years, with similar figures reported in 2023, where total emissions were also about 101,568,000 kg CO2e. Alkem Laboratories has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. The company has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, which suggests that while emissions are being tracked, formal commitments to reduction strategies are currently absent. The emissions intensity for Scope 1 and Scope 2 combined is reported at approximately 2.334e-05 kg CO2e per rupee of turnover, with a physical output intensity of about 2,140 kg CO2e per tonne. This data highlights the company's operational efficiency in relation to its emissions. Overall, while Alkem Laboratories has made strides in emissions reporting, the absence of reduction targets and commitments may limit its climate leadership within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 15,773,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 78,502,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Alkem Laboratories's Industry?
How Carbon Intensive is Alkem Laboratories's Location?
Alkem Laboratories's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Alkem Laboratories has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
